We Develop High-Quality Biosimilars. For Better Access to Vital Medicines.

Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company's activities span the entire range from technical-pharmaceutical development to clinical trials, all the way through to preparation of dossiers for regulatory approval.

Half-Year Report 2024

Formycon. The Biosimilar Experts.

COVID-19 Project: FYB207

An innovative antiviral drug based on a long-acting ACE2-IgG-Fc fusion molecule

Discover Formycon

Biosimilar developer with unique expertise

Latest News News Upcoming Events Events Publications Publications

Formycon and Fresenius Kabi receive FDA approval for FYB202/Otulfi™ (ustekinumab-aauz)

September 30, 2024

FDA grants approval for Stelara® Biosimilar FYB202/Otulfi™ (ustekinumab-aauz)

September 27, 2024

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases

September 27, 2024

Meet your New Colleagues

Formycon’s employees are the foundation of our success. We strongly believe that an appreciative corporate culture contributes significantly to our progress. Therefore, we cultivate a culture of diversity and mutual appreciation.

We offer you the opportunity for rapid career advancement in a dynamic, high-growth environment where professionalism and team spirit form the foundation of our daily cooperation.

Explore your career opportunities